MET and steatosis: Activation of the MET pathway has been known to ameliorate alcoholic steatohepatitis and liver fibrosis or cirrhosis in pre-clinical models of liver disease (Matsuda et al, 1995;, Matsuda, 1997;, Tahara et al, 1999;, Taïeb et al, 2002), and conversely, deletion of the MET gene in postnatal mice causes hyperlipidemia, severe steatosis, and progressive liver disease (Kroy et al, 2014).